Skip to main content
. Author manuscript; available in PMC: 2021 Apr 27.
Published in final edited form as: Kidney Int. 2020 Jul 25;99(3):716–724. doi: 10.1016/j.kint.2020.06.037

Figure 3: CKD incidence or progression event rates per 1000 patient-years by biomarker tertile and clinical AKI status.

Figure 3:

*The event rate in the highest tertile of the injury biomarkers (bFGF, KIM-1, TNFr1) in those without clinical AKI are similar to the event rate in the lowest tertile of the biomarker in those with clinical AKI. The event rates for all tertiles of NT pro-BNP are lower in those without clinical AKI compared to those with clinical AKI.